

ASX Announcement

Results of Annual General Meeting

Sydney, Australia, 14 November 2024: Imugene Limited (ASX:IMU) (Imugene, or the Company) is pleased to announce the results of today's Annual General Meeting.

The results are set out in the attached document, in accordance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the Corporation's Act.

All resolutions were carried and decided by way of a poll.

In accordance with ASX Listing Rule 3.12.2(f), the Company advises that more than 25% of the votes cast on Resolution 1 were against the adoption of the 2024 Remuneration Report and therefore constitutes a "first strike" under section 250U of the Corporations Act.

Release approved by the Company Secretary on behalf of the Board.

For more information please contact:

Leslie Chong
Managing Director and Chief Executive Officer
info@imugene.com

General Investor Enquiries
shareholderenquiries@imugene.com

Media Enquiries
Matt Wright
matt@nwrcommunications.com.au

Connect with us on LinkedIn @Imugene Limited
Follow us on Twitter @TeamImugene
Watch us on YouTube @ImugeneLimited



About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

For personal use only

Disclosure of Proxy Votes

Imugene Limited

Annual General Meeting

Thursday, 14 November 2024



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 DIRECTORS' REMUNERATION REPORT	P	1,729,073,569	1,089,828,777 63.03%	628,716,068 36.36%	42,226,132	10,528,724 0.61%	1,105,321,151 63.78%	627,618,353 36.22%	42,626,132	-
2 RE-ELECTION OF DIRECTOR – DR LESLEY RUSSELL	P	1,995,291,153	1,650,737,482 82.73%	286,477,945 14.36%	58,973,092	58,075,726 2.91%	1,713,079,143 85.67%	286,477,945 14.33%	58,973,092	Carried
3 RATIFICATION OF PRIOR ISSUE OF SUBSCRIPTION SHARES TO PRECISION BIOSCIENCES INC. (NASDAQ GS: DTIL)	P	1,924,774,214	1,840,637,826 95.63%	70,990,253 3.69%	68,202,430	13,146,135 0.68%	1,856,999,896 96.32%	70,990,253 3.68%	69,252,430	Carried
4 ISSUE OF PERFORMANCE RIGHTS TO DIRECTOR – MR PAUL HOPPER	P	1,769,124,621	1,017,761,773 57.53%	739,158,489 41.78%	285,718,809	12,204,359 0.69%	1,032,204,703 58.21%	741,185,853 41.79%	285,718,809	Carried
5 ISSUE OF PERFORMANCE RIGHTS TO DIRECTOR – MS LESLIE CHONG	P	1,930,894,200	1,231,703,662 63.79%	688,759,887 35.67%	38,238,814	10,430,651 0.54%	1,246,597,963 64.42%	688,562,172 35.58%	38,238,814	Carried
6 ISSUE OF RESTRICTED STOCK UNITS TO DIRECTOR – DR JAKOB DUPONT	P	2,004,026,423	1,392,432,649 69.48%	599,272,785 29.90%	50,817,611	12,320,989 0.61%	1,407,069,573 70.06%	601,222,785 29.94%	50,817,611	Carried
7 ISSUE OF RESTRICTED STOCK UNITS TO DIRECTOR – DR JENS ECKSTEIN	P	1,981,126,208	1,336,396,059 67.46%	634,148,597 32.01%	73,717,826	10,581,552 0.53%	1,346,441,261 67.82%	638,950,882 32.18%	73,717,826	Carried
8 ISSUE OF RESTRICTED STOCK UNITS TO DIRECTOR – DR LESLEY RUSSELL	P	1,982,864,461	1,337,321,403 67.44%	634,961,506 32.02%	51,741,478	10,581,552 0.53%	1,350,218,890 67.95%	636,911,506 32.05%	51,741,478	Carried

For personal use only



For personal use only

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
9 ISSUE OF RESTRICTED STOCK UNITS TO DIRECTOR – MS KIM DRAPKIN	P	2,003,245,755	1,369,505,512 68.36%	621,375,437 31.02%	51,229,231	12,364,806 0.62%	1,384,186,253 68.95%	623,325,437 31.05%	51,229,231	Carried

